Drug intelligence / Profile preview

paclitaxel + pictilisib + trastuzumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination therapy consisting of paclitaxel (a taxane chemotherapy agent), pictilisib (a pan-phosphatidylinositol 3-kinase inhibitor), and trastuzumab (a humanized monoclonal antibody targeting HER2). The combination has been studied in clinical trials for patients with HER2-positive breast cancer. Paclitaxel works by stabilizing microtubules and preventing cell division, pictilisib inhibits the PI3K/AKT/mTOR pathway (which is associated with trastuzumab resistance), and trastuzumab targets the HER2 protein overexpressed in certain breast cancers. This triple combination aims to enhance antitumor activity and potentially overcome resistance mechanisms.

Other names: pictilisib + paclitaxel + trastuzumab

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)

Beyond the preview

Go deeper on paclitaxel + pictilisib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + pictilisib + trastuzumab.

Explore the full profile